Eisai Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eisai Co., Ltd.
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.
Abbott's s Christopher Calamari, Gerber's Scott Fitz and Reckitt Robert Cleveland didn't have ng answers about immediately solving supply shortage or about preventing another one when they testified before Oversight and Investigation Subcommittee.
Democrats on Oversight and Investigation Subcommittee support increasing funding for FDA’s regulation of food product manufacturing and marketing, but Republicans advise Commissioner Robert Califf the agency should do more with authority it already has and without adding to its budget.
Commissioner Robert Califf wants Janet Woodcock to improve food operations and processes, but lawmakers question whether she is the best overseer for the area.
- Other Names / Subsidiaries
- EA Pharma Co., Ltd.
- Eisai China Inc
- Eisai Laboratorios
- Eisai Mexico
- Eisai Participacoes Ltda. (Brazil Subsidiary)
- H3 Biomedicine
- HI-Eisai Pharmaceutical Inc.
- Jingyi Weixiang (Shanghai) Health Industry Development Limited
- Liaoning TianYi Biological Pharmaceutical Co., Ltd.
- KAN Research Institute, Inc.
- MGI Pharma, Inc.
- Morphotek, Inc.
- Zycos Inc.
- Eisai Vietnam Co., Ltd.